EGFR (L747S)

EGFR · Variant type: point · HGVS: p.L747S

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Gefitinib	100.0%	0.0%	99.25
2	Afatinib	100.0%	0.0%	98.50
3	Pralsetinib	99.9%	0.1%	93.43
4	Mobocertinib	99.9%	0.1%	97.22
5	Canertinib	99.6%	0.4%	96.49
6	Lazertinib	99.5%	0.5%	97.47
7	Ibrutinib	99.3%	0.7%	94.74
8	Osimertinib	99.2%	0.8%	97.24
9	Dacomitinib	99.1%	0.9%	97.99
10	Erlotinib	98.8%	1.2%	99.75
11	Neratinib	98.2%	1.9%	93.18
12	Bosutinib	97.6%	2.4%	87.22
13	Brigatinib	97.4%	2.6%	82.96
14	Lapatinib	97.3%	2.7%	99.25
15	Vandetanib	96.8%	3.2%	95.74
16	Fostamatinib	92.8%	7.2%	96.74
17	Defactinib	89.7%	10.3%	92.68
18	Alpelisib	85.9%	14.1%	97.22
19	Dasatinib	84.8%	15.2%	87.97
20	Pacritinib	84.2%	15.8%	88.64
21	Alectinib	81.5%	18.5%	95.49
22	Ponatinib	77.4%	22.6%	78.23
23	Zanubrutinib	73.8%	26.2%	98.24
24	Capmatinib	71.0%	29.0%	99.75
25	Gilteritinib	47.4%	52.6%	88.97

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Gefitinib	100.0%	99.9%	+0.1%
Afatinib	100.0%	100.0%	+0.0%
Pralsetinib	99.9%	99.1%	+0.8%
Mobocertinib	99.9%	100.0%	-0.1%
Canertinib	99.6%	98.4%	+1.2%
Lazertinib	99.5%	100.0%	-0.5%
Ibrutinib	99.3%	99.3%	-0.0%
Osimertinib	99.2%	99.1%	+0.1%
Dacomitinib	99.1%	99.8%	-0.7%
Erlotinib	98.8%	99.4%	-0.6%
Neratinib	98.2%	100.0%	-1.8%
Bosutinib	97.6%	99.3%	-1.7%
Brigatinib	97.4%	98.5%	-1.1%
Lapatinib	97.3%	99.2%	-1.8%
Vandetanib	96.8%	99.3%	-2.6%
Fostamatinib	92.8%	97.8%	-5.0%
Defactinib	89.7%	94.6%	-4.9%
Alpelisib	85.9%	—	—
Dasatinib	84.8%	97.9%	-13.2%
Pacritinib	84.2%	—	—
Alectinib	81.5%	—	—
Ponatinib	77.4%	—	—
Zanubrutinib	73.8%	88.2%	-14.4%
Capmatinib	71.0%	—	—
Gilteritinib	47.4%	91.0%	-43.6%

Cancer	Organ	Source
carcinoma_lung	Lung	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.8ms